Literature DB >> 26253723

Reduced Serum Level of Interleukin-10 is Associated with Cerebral Infarction: A Case-Control and Meta-Analysis Study.

Yifei Zhu1, Haiqing Yang2, Zengyan Diao3, Yi Li3, Chuanzhu Yan4.   

Abstract

IL-10 expression limits inflammation and restricts the size of CNS damage from stroke. In this study, we examined the correlation between cerebral infarction (CI) and serum levels of interleukin-10 (IL-10) using a combination of case-control study and meta-analysis of published data, with an aim of understanding the relevance of serum IL-10 levels to CI development. This study enrolled a total of 169 CI patients admitted to the Second Hospital of Hebei Medical University between May 2011 and November 2014. During the same period, a group of 145 individuals were recruited at the same hospital as healthy controls after thorough physical examination. Serum IL-10 levels were measured by enzyme-linked immunosorbent assay (ELISA). SPSS 19.0 (IBM, 2010, Chicago, IL, USA) and Comprehensive Meta-Analysis 2.0 (CMA 2.0) software were used for data analysis. Serum levels of IL-10 (pg/mL) were significantly lower in CI patients when compared to healthy controls (15.36 ± 3.21 vs. 21.64 ± 5.17, t = 13.12, P < 0.001). In addition, patients with large artery atherosclerosis (LAAS), cardioembolic infarct (CEI), and lacunar infarct (LAC) displayed drastically reduced serum levels of IL-10 (pg/mL) compared to healthy controls (LAAS 14.77 ± 5.21, CEI 15.25 ± 5.10, LAC 16.58 ± 4.92, all P < 0.001). Interestingly, no significant differences were observed in the serum IL-10 levels when pair-wise comparisons were made between these three clinical subtypes of CI (all P > 0.05). Logistic regression analysis indicated that, with the exception of triglyceride (TG) and uric acid (UA) levels (both P > 0.05), the other seven parameters, including fasting blood glucose (FPG), total cholesterol, low-density lipoprotein (LDL), high-density lipoprotein (HDL), creatinine (Cr), systolic blood pressure (SBP), and diastolic blood pressure (DBP), strongly correlated with CI development (all P < 0.05). Meta-analysis of pooled data from nine case-control studies revealed an inverse correlation between the serum IL-10 levels and CI (SMD = 1.797, 95% CI 0.785~2.810, P = 0.001). Subgroup analysis based on country showed that low serum levels of IL-10 may be the major risk factor for CI in Croatia (SMD = 2.961, 95% CI 2.480~3.443, P < 0.001) and India (SMD = 1.440, 95% CI 1.129-1.750, P < 0.001). Further, subgroup analysis based on ethnicity showed that IL-10 serum levels and CI displayed negative relationship in Asians (SMD = 2.522, 95% CI 0.468~4.576, P = 0.016) but not in Caucasians (P > 0.05). Our study provided convincing evidence that the patients with CI exhibit consistently reduced serum levels of IL-10, and IL-10 may be a major player in the development and progression of CI.

Entities:  

Keywords:  Anti-inflammatory cytokines; Cardioembolic infarct; Case-control study; Cerebral infarction; IL-10; Inflammatory cytokines; Lacunar infarct; Large artery atherosclerosis

Mesh:

Substances:

Year:  2015        PMID: 26253723     DOI: 10.1007/s12035-015-9368-y

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  24 in total

Review 1.  The extended IL-10 superfamily: IL-10, IL-19, IL-20, IL-22, IL-24, IL-26, IL-28, and IL-29.

Authors:  Scott Commins; John W Steinke; Larry Borish
Journal:  J Allergy Clin Immunol       Date:  2008-04-11       Impact factor: 10.793

2.  World Medical Association publishes the Revised Declaration of Helsinki.

Authors:  P Nischal M
Journal:  Natl Med J India       Date:  2014 Jan-Feb       Impact factor: 0.537

3.  Risk factor burden predicts long-term mortality after cerebral infarction.

Authors:  G Gjerde; H Naess
Journal:  Acta Neurol Scand       Date:  2013-06-27       Impact factor: 3.209

4.  Elevated plasma levels of neuropeptide proenkephalin a predict mortality and functional outcome in ischemic stroke.

Authors:  Wolfram Doehner; Stephan von Haehling; Jennifer Suhr; Nicole Ebner; Andreas Schuster; Eike Nagel; Arthur Melms; Thomas Wurster; Konstantinos Stellos; Meinrad Gawaz; Boris Bigalke
Journal:  J Am Coll Cardiol       Date:  2012-07-24       Impact factor: 24.094

5.  Significance of plasma adiponectin for diagnosis, neurological severity and functional outcome in ischemic stroke - Research for Biomarkers in Ischemic Stroke (REBIOS).

Authors:  Takahiro Kuwashiro; Tetsuro Ago; Masahiro Kamouchi; Ryu Matsuo; Jun Hata; Junya Kuroda; Kenji Fukuda; Hiroshi Sugimori; Masayo Fukuhara; Hideto Awano; Tetsu Isomura; Kazuo Suzuki; Masahiro Yasaka; Yasushi Okada; Yutaka Kiyohara; Takanari Kitazono
Journal:  Metabolism       Date:  2014-05-02       Impact factor: 8.694

6.  A method of moments estimator for random effect multivariate meta-analysis.

Authors:  Han Chen; Alisa K Manning; Josée Dupuis
Journal:  Biometrics       Date:  2012-05-02       Impact factor: 2.571

7.  Functional polymorphisms of interleukin 4 and interleukin 10 may predict evolution and functional outcome of an ischaemic stroke.

Authors:  S Marousi; J Ellul; A Antonacopoulou; C Gogos; P Papathanasopoulos; M Karakantza
Journal:  Eur J Neurol       Date:  2010-09-28       Impact factor: 6.089

Review 8.  IL-10 and IL-10 receptor defects in humans.

Authors:  Erik-Oliver Glocker; Daniel Kotlarz; Christoph Klein; Neil Shah; Bodo Grimbacher
Journal:  Ann N Y Acad Sci       Date:  2011-12       Impact factor: 5.691

9.  Immuno-inflammatory activation in acute cardio-embolic strokes in comparison with other subtypes of ischaemic stroke.

Authors:  Giuseppe Licata; Antonino Tuttolomondo; Domenico Di Raimondo; Salvatore Corrao; Riccardo Di Sciacca; Antonio Pinto
Journal:  Thromb Haemost       Date:  2009-05       Impact factor: 5.249

10.  Long-term mortality after stroke among adults aged 18 to 50 years.

Authors:  Loes C A Rutten-Jacobs; Renate M Arntz; Noortje A M Maaijwee; Henny C Schoonderwaldt; Lucille D Dorresteijn; Ewoud J van Dijk; Frank-Erik de Leeuw
Journal:  JAMA       Date:  2013-03-20       Impact factor: 56.272

View more
  5 in total

1.  The correlation study on homocysteine, blood lipids and blood glucose levels in patients with cerebral infarction.

Authors:  Wen-Ling Li; Hua Sang; Xin Xu; Yuan-Yuan Zhang; Jie Gao; Bo-Hua Chen; Xiang-Ying Meng
Journal:  Am J Transl Res       Date:  2021-05-15       Impact factor: 4.060

2.  Inflammatory cytokines and ischemic stroke risk: The REGARDS cohort.

Authors:  Nancy Swords Jenny; Peter W Callas; Suzanne E Judd; Leslie A McClure; Brett Kissela; Neil A Zakai; Mary Cushman
Journal:  Neurology       Date:  2019-04-19       Impact factor: 9.910

3.  Association between genetic polymorphisms of interleukins and cerebral infarction risk: a meta-analysis.

Authors:  Jiantao Wang; Niannian Fan; Yili Deng; Jie Zhu; Jing Mei; Yao Chen; Heng Yang
Journal:  Biosci Rep       Date:  2016-11-03       Impact factor: 3.840

4.  Clinical Efficacy Evaluation and Potential Mechanism of Zhishe Tongluo Capsule in the Treatment of Cerebral Infarction by Meta-Analysis Associated with Network Pharmacology.

Authors:  Zhi Xin Geng; Feng Gao; Junjing Guo; Bingzhou Guo; Chunyu Liu; Taiwei Dong; Min Li; Yang Bai; Peifeng Wei
Journal:  Evid Based Complement Alternat Med       Date:  2022-01-10       Impact factor: 2.629

5.  The Prognostic Determinant of Interleukin-10 in Patients with Acute Ischemic Stroke: An Analysis from the Perspective of Disease Management.

Authors:  Wen Sun; Shuhui Wang; Shanji Nan
Journal:  Dis Markers       Date:  2021-07-17       Impact factor: 3.434

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.